Skip to main content
[Preprint]. 2020 Feb 25:3541361. [Version 1] doi: 10.2139/ssrn.3541361

Table 3.

Dominant SARS-CoV-derived T cell epitopes and corresponding regions in nCoV

SARS 2019 nCoV
Sequence RF score HLA restrictiona Sequence Proteinb Mapped Start-End Identity (%)
VRGWVFGSTMNNKSQSVI 0.15 DRB1*04:01 IRGWIFGTTLDSKTQSLL s 101-118 50
CTFEYISDAFSLD 0.21 DRB1*04:01 CTFEYVSQPFLMD S 166-178 62
DAFSLDVSEKSGN 0.62 DRB1*04:01 QPFLMDLEGKQGN s 173-185 38
TNFRAILTAFSPAQDIW 0.32 DRB1*04 01 TRFQTLLALHRSYLTPGDSSSGW s 236-258 17
KSFEIDKGIYQTSNFRW 0.40 DRB 1*04:01, DRB1*07:01 KSFTVEKGIYQTSNFRVQ s 304-321 78
STFFSTFKCYGVSATKL 0.50 DRB 1*07:01, DR8 SASFSTFKCYGVSPTKL s 371-387 82
KLPDDFMGCV 0.55 A*02:01 KLPDDFTGCV s 424-433 90
NIDATSTGNYNYKYRYLR 0.29 NLDSKVGGNYNYLYRLFR g 440-457 56
YLRHGKLRPFERDISNVP 0.16 DRB1*04:01 YLYRLFRKSNLKPFERDI s 451-468 58
RPFERDISNVPFS 0.36 DRB1*04:01 KPFERDISTEIYQ s 462-474 54
KSIVAYTMSLGADSSIAY 0.15 DRB1*04:01, DRB1*07:01 QSIIAYTMSLGAENSVAY s 690-707 72
SIVAYTMSL 0.29 A*02:01 SIIAYTMSL s 691-699 89
TECANLLLQYGSFCTQL 0.50 DR8 TECSNLLLQYGSFCTQL s 747-763 94
VKQMYKTPTLKYFGGFNF 0.20 DRB1*04:01 VKQIYKTPPIKDFGGFNF s 785-802 78
ESLTTTSTALGKLQDW 0.42 DRB1*04:01 DSLSSTASALGKLQDW s 936-952 71
ALNTLVKQL 0.29 A*02:01 ALNTLVKQL s 958-966 100
VLNDILSRL 0.29 A*02:01 VLNDILSRL s 976-984 100
LITGRLQSL 0.42 A*02:01 LITGRLQSL s 996-1004 100
QLIRAAEIRASANLAATK 0.20 DRB1*04:01 QLIRAAEIRASANLAATK s 1011-1028 100
SWFITQRNFFSPQII 0.60 DRB1*04:01 HWFVTQRNFYEPQII s 1101-1115 73
RLNEVAKNL 0.42 A*02:01 RLNEVAKNL s 1185-1193 100
NLNESLIDL 0.29 A*02:01 NLNESLIDL s 1192-1200 100
FIAGLIAIV 0.80 A*02:01 FIAGLIAIV s 1220-1228 100
RFFTLGSITAQPVKI 0.18 B*58:01 RIFTIGTVTLKQGEI Orf 3a 6-20 40
SITAQPVKI 0.29 B*58:01 TVTLKQGEI Orf 3a 12-20 22
TLACFVLAAV 0.59 A*02:01 TLACFVLAAV M 61-70 100
GLMWLSYFV 0.59 A*02:01 GLMWLSYFI M 89-97 89
HLRMAGHSL 0.40 Class I HLRIAGHHL M 148-156 78
ALNTPKDHI 0.29 A*02:01 ALNTPKDHI N 138-146 100
LQLPQGTTL 0.29 A*02:01 LQLPQGTTL N 159-167 100
GETALALLLL 0.38 B*40:01 GDAALALLLL N 215-224 80
LALLLLDRL 0.29 A*02:01 LALLLLDRL N 219-227 100
LLLDRLNQL 0.42 A*02:01 LLLDRLNQL N 222-230 100
RLNQLESKV 0.42 A*02:01 RLNQLESKM N 226-234 89
TKQYNVTQAF 0.29 Class I TKAYNVTQAF N 265-274 90
GMSRIGMEV 0.42 A*02:01 GMSRIGMEV N 316-324 100
MEVTPSGTWL 0.42 B*40:01 MEVTPSGTWL N 322-331 100
QFKDNVILL 0.50 A*24:02 NFKDQVILL N 345-353 78
CLDAGINYV 0.42 A*02:01 CLEASFNYL Orf lab 2139-2147 56
WLMWFIISI 0.42 A*02:01 WLMWLIINL Orf lab 2292-2300 67
ILLLDQVLV 0.42 A*02:01 ILLLDQALV Orf lab 2498-2506 89
LLCVLAALV 0.42 A*02:01 SACVLAAEC Orf lab 2840-2848 56
ALSGVFCGV 0.42 A*02:01 SLPGVFCGV Orf lab 2942-2950 78
TLMNVITLV 0.42 A*02:01 TLMNVLTLV Orf lab 3639-3647 89
SMWALVISV 0.42 A*02:01 SMWALIISV Orf lab 3661-3669 89
a.

Restrictions defined only in HLA-transgenic mice are indicated by the italicized font.

b.

S= surface glycoprotein; M=membrane protein; N=nucleocapsid phosphoprotein.